The shares of YY Inc. have decreased by more than -19.10% this year alone. The shares recently went down by -5.71% or -$5.54 and now trades at $91.47. The shares of Protalix BioTherapeutics, Inc. (NYSE:PLX), has slumped by -28.92% year to date as of 04/13/2018. The shares currently trade at $0.47 and have been able to report a change of 2.20% over the past one week.
The stock of YY Inc. and Protalix BioTherapeutics, Inc. were two of the most active stocks on Friday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.Next 5Y EPS Growth: 3.28% versus 25.00%
When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that YY will grow it’s earning at a 3.28% annual rate in the next 5 years. This is in contrast to PLX which will have a positive growth at a 25.00% annual rate. This means that the higher growth rate of PLX implies a greater potential for capital appreciation over the years.Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. YY has an EBITDA margin of 19.02%, this implies that the underlying business of YY is more profitable. These figures suggest that YY ventures generate a higher ROI than that of PLX.Cash Flow
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, YY’s free cash flow per share is a positive 0, while that of PLX is positive 0.1.Valuation
YY currently trades at a forward P/E of 9.01, a P/B of 3.42, and a P/S of 3.32 while PLX trades at a forward P/E of 2.47, and a P/S of 3.56. This means that looking at the earnings, book values and sales basis, YY is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of YY is currently at a -40.7% to its one-year price target of 154.24. Looking at its rival pricing, PLX is at a -86.76% relative to its price target of 3.55.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), YY is given a 1.60 while 1.50 placed for PLX. This means that analysts are more bullish on the outlook for YY stocks.Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for YY is 0.70 while that of PLX is just 5.87. This means that analysts are more bullish on the forecast for YY stock.
The stock of YY Inc. defeats that of Protalix BioTherapeutics, Inc. when the two are compared, with YY taking 5 out of the total factors that were been considered. YY happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, YY is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for YY is better on when it is viewed on short interest.